Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Specialty pharma company Mallinckrodt PLC (NYSE:MNK) reported disappointing results before the open Tuesday,with the weakness stemming from soft sales of its key drug Acthar, which fetched roughly 52 percent of the total sales.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Acthar gel is an injectable formulation used to treat infantile spasms and acute exacerbation of multiple sclerosis. Sales of this key product fell 5.6 percent year-over-year in the quarter, trailing most analyst estimates.
The Analyst
Barclays analyst Douglas Tsao reviewed the results of Mallinckrodt.
The Rating
The firm downgraded the shares of Mallinckrodt from Overweight to Equal-weight and lowered the price target to $23. The downgrade is based on disappointing Q3 results and a lack of visibility for Acthar, according to Barclays.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The Thesis
The weakness wasn't isolated to Acthar, with specialty generics sales for Mallinckrodt declining 21.1 percent, Tsao said. (See Tsao's track record here.)
Though noting that the drop was in line with previous guidance, the analyst said he was surprised by the magnitude of the sequential drop.
Mallinckrodt expects the Active Pharmaceutical Ingredient — or API — business to offer some semblance of stability despite the ongoing challenges, Tsao said.
See also: Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon
On other products, Barclays said INOmax sales trailed expectations. INOmax' existing customers are projected to remain durable, but Tsao said customer retention might be tough if a low-cost competitor emerges. Barclays termed Therakos as a bright spot in the quarter.
Following the Q3 report, Barclays said Mallinckrodt's stock price is less likely to appreciate. Despite the strong cash flow generation in the quarter, Barclays does not see sufficient capacity for the drugmaker to pursue diversifying M&A near term.
The Price Action
At the time of writing, shares of Mallinckrodt were slipping 2.69 percent to $19.57, extending the nearly 36-percent slide on Tuesday in reaction to the quarterly results.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.